Braun-Bostich & Associates’s AstraZeneca AZN Stock Holding History

Braun-Bostich & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,096	Closed	-$201K	–	128
2025 Q4	$201K	Buy	+1,096	New	+$192K	0.12%	124
2024 Q4	–	Sell	-1,323	Closed	-$206K	–	109
2024 Q3	$206K	Buy	+1,323	New	+$214K	0.14%	111
2022 Q1	–	Sell	-5,049	Closed	-$602K	–	74
2021 Q4	$602K	Buy	+5,049	New	+$594K	0.14%	56
2018 Q2	–	Sell	-808	Closed	-$56K	–	304
2018 Q1	$56K	Hold	808	–	–	0.05%	166
2017 Q4	$56K	Buy	+808	New	+$54.5K	0.05%	170

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Braun-Bostich & Associates's AZN Position: Q1 2026 in Review

Braun-Bostich & Associates sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,096 shares — an estimated $201K sold.

Braun-Bostich & Associates first reported a position in AZN in Q4 2017 and held it in 5 quarters. The position peaked at $602K in Q4 2021. 1,385 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Braun-Bostich & Associates reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Braun-Bostich & Associates sold 1,096 AstraZeneca shares in Q1 2026, an estimated $201K.
Braun-Bostich & Associates first reported a position in AstraZeneca in Q4 2017 and held it in 5 quarters.
Braun-Bostich & Associates's AstraZeneca position peaked at $602K in Q4 2021.
1,385 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Braun-Bostich & Associates's 13F filing for Q1 2026, filed 15 Apr 2026.